ATE176400T1 - Therapeutische verwendungen von melanin - Google Patents

Therapeutische verwendungen von melanin

Info

Publication number
ATE176400T1
ATE176400T1 AT92902038T AT92902038T ATE176400T1 AT E176400 T1 ATE176400 T1 AT E176400T1 AT 92902038 T AT92902038 T AT 92902038T AT 92902038 T AT92902038 T AT 92902038T AT E176400 T1 ATE176400 T1 AT E176400T1
Authority
AT
Austria
Prior art keywords
melanin
active substance
disease
toxin
mammal
Prior art date
Application number
AT92902038T
Other languages
English (en)
Inventor
David L Berliner
Robert L Erwin
David R Mcgee
Original Assignee
Biosource Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosource Tech Inc filed Critical Biosource Tech Inc
Application granted granted Critical
Publication of ATE176400T1 publication Critical patent/ATE176400T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/22—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0055—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
    • C12N9/0057—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3)
    • C12N9/0059—Catechol oxidase (1.10.3.1), i.e. tyrosinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y110/00—Oxidoreductases acting on diphenols and related substances as donors (1.10)
    • C12Y110/03—Oxidoreductases acting on diphenols and related substances as donors (1.10) with an oxygen as acceptor (1.10.3)
    • C12Y110/03001—Catechol oxidase (1.10.3.1), i.e. tyrosinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/18—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with another compound as one donor, and incorporation of one atom of oxygen (1.14.18)
    • C12Y114/18001—Tyrosinase (1.14.18.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AT92902038T 1990-11-05 1991-11-05 Therapeutische verwendungen von melanin ATE176400T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/609,311 US5210076A (en) 1988-09-13 1990-11-05 Methods of treating Parkinson's disease using melanin

Publications (1)

Publication Number Publication Date
ATE176400T1 true ATE176400T1 (de) 1999-02-15

Family

ID=24440247

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92902038T ATE176400T1 (de) 1990-11-05 1991-11-05 Therapeutische verwendungen von melanin

Country Status (9)

Country Link
US (4) US5210076A (de)
EP (1) EP0510186B1 (de)
JP (3) JPH05503308A (de)
AT (1) ATE176400T1 (de)
AU (1) AU9028891A (de)
CA (1) CA2073180C (de)
DE (1) DE69130859T2 (de)
ES (1) ES2131525T3 (de)
WO (1) WO1992007580A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874091A (en) * 1990-09-27 1999-02-23 L'oreal Cosmetic composition comprising a dispersion of lipid vesicles as well as melanin pigments
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US7556825B2 (en) * 1993-04-02 2009-07-07 Anticancer, Inc. Method for promoting hair growth
ATE209887T1 (de) 1993-04-02 2001-12-15 Anticancer Inc Verfahren zur verabreichung von förderlichen zusammensetzungen auf die haarfollikel
US5643554A (en) * 1993-04-30 1997-07-01 Dusa Pharmaceuticals, Inc. Lipomelanim composition
US5750119A (en) * 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5716614A (en) * 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
US5824692A (en) * 1995-01-06 1998-10-20 Lippiello; Patrick Michael Pharmaceutical compositions for prevention and treatment of central nervous system disorders
US5616707A (en) * 1995-01-06 1997-04-01 Crooks; Peter A. Compounds which are useful for prevention and treatment of central nervous system disorders
US5583140A (en) * 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
US5849708A (en) * 1995-06-06 1998-12-15 Joslin Diabetes Center, Inc. Promotion of eating behavior
WO1997040011A1 (en) 1996-04-23 1997-10-30 R. J. Reynolds Tobacco Company Pharmaceutical compositions for prevention and treatment of central nervous system disorders
US6623724B2 (en) * 1996-09-18 2003-09-23 Applied Genetics Incorporated Dermatics Dermatological compositions and methods
US6214888B1 (en) * 1996-09-18 2001-04-10 Applied Genetics Incorporated Dermatological compounds
US6242415B1 (en) * 1997-02-12 2001-06-05 Sri International Mediation of cytokines by melanin
US5817048A (en) * 1997-03-20 1998-10-06 Brown University Research Foundation Ultrasonic alternative to laser-based photodynamic therapy
US6756056B2 (en) * 1997-04-08 2004-06-29 Alan A. Rubin Treatment of Parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa
DE19718826A1 (de) * 1997-05-05 1998-11-12 Marion S Dr Eckmiller Verwendung biologisch aktiver Wirkstoffe zum Beeinflussen des Extrazellulär-Raumes von Sinneszellen und Verfahren zur Wirkstoff-Administrationssteuerung
US7214686B2 (en) * 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
US5980914A (en) * 1997-08-22 1999-11-09 P.N. Gerolymatos S.A. Clioquinol for the treatment of Parkinson's disease
AU4215499A (en) * 1998-05-28 2002-07-08 Codon Pharmaceuticals, Inc. Treatment of neurodegenerative diseases
US6506378B1 (en) 1998-12-16 2003-01-14 Arch Development Corporation Vesicular monoamine transporter gene therapy in Parkinson's disease
WO2001003649A2 (en) 1999-07-13 2001-01-18 Alpha Research Group, Llc Compositions and methods for the treatment of parkinson's disease
US20040229908A1 (en) * 1999-07-13 2004-11-18 Jodi Nelson Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias
AU2001246877A1 (en) * 2000-04-11 2001-10-23 Takara Bio Inc. Remedies
US6855925B2 (en) * 2001-02-14 2005-02-15 Picoliter Inc. Methods, devices, and systems using acoustic ejection for depositing fluid droplets on a sample surface for analysis
DE10206723A1 (de) 2002-02-18 2003-09-04 Ulrich Schraermeyer Therapie von Erkrankungen des Auges und des Zentralen Nervensystems
US6942663B2 (en) * 2002-03-12 2005-09-13 Board Of Regents, The University Of Texas System Laser treatment of cutaneous vascular lesions
JP4724421B2 (ja) * 2002-10-08 2011-07-13 アラーガン、インコーポレイテッド 神経変性を処置するためのα２Ｂまたは２Ｂ／２Ｃアドレナリン受容体アゴニスト
US20040116436A1 (en) * 2002-10-08 2004-06-17 Tatton William G. Treatment of dementia and parkinson's disease
ATE433993T1 (de) 2003-02-26 2009-07-15 Univ Johns Hopkins Modulatorische verbindungen und verfahren für glutamattransport
US20040242729A1 (en) * 2003-05-30 2004-12-02 3M Innovative Properties Company Stabilized particle dispersions containing surface-modified inorganic nanoparticles
CA2535663C (en) * 2003-08-12 2011-02-08 Paul Alan Cox Neurotoxic amino acid or neurotoxic derivative thereof associated with neurological disorders
EP1678172B1 (de) * 2003-10-15 2009-12-09 Targacept, Inc. Azabicyclische verbindungen zur linderung von schmerzen und zur behandlung von erkrankungen des zentralen nervensystems
US7790226B2 (en) * 2003-10-27 2010-09-07 California Institute Of Technology Pyrolyzed thin film carbon
WO2005070005A2 (en) * 2004-01-23 2005-08-04 California Institute Of Technology Pyrolyzed thin film carbon
WO2006015115A2 (en) * 2004-07-30 2006-02-09 University Of Mississippi Potent immunostimulatory extracts from microalgae
JP2006076946A (ja) * 2004-09-10 2006-03-23 Hoyu Co Ltd 重金属及び／又は放射性物質の排泄、又は除去を用途とするメラニン類含有組成物、及びメラニン類の用途
JP4578221B2 (ja) * 2004-12-08 2010-11-10 月桂冠株式会社 メラニン前駆体の製造方法
US8673983B2 (en) * 2007-12-21 2014-03-18 Loyola University Chicago Melanins synthesized chemically or via enzyme catalysis
JP2010115213A (ja) * 2010-03-02 2010-05-27 Gekkeikan Sake Co Ltd メラニン前駆体の製造方法
WO2012129047A1 (en) * 2011-03-18 2012-09-27 Albert Einstein College Of Medicine Of Yeshiva University Oral administration of melanin for protection against radiation
US8610970B1 (en) * 2011-08-20 2013-12-17 Darwin Hu Liquid crystal display (LCD) scanners
RU2672564C2 (ru) * 2014-09-09 2018-11-16 Эррера Артуро Солис Способы лечения и предотвращения заболеваний глаз, расстройств и патологических состояний меланином и аналогами, предшественниками и производными меланина
KR101749675B1 (ko) * 2015-07-20 2017-06-26 동국대학교 산학협력단 멜라닌 응집 호르몬을 유효성분으로 포함하는 파킨슨병 치료 및 레보도파 부작용 억제용 약학 조성물
WO2017065541A1 (ko) * 2015-10-15 2017-04-20 동국대학교 산학협력단 퇴행성 뇌질환의 예방 또는 치료용 조성물
EP3173098A1 (de) * 2015-11-27 2017-05-31 Assistance Publique-Hopitaux De Paris Immunstimulierende zusammensetzungen
US11266629B2 (en) 2016-05-02 2022-03-08 Goodwin & Wells LLC Melanin compositions and devices for protecting tissues from radiation damage
US11298379B2 (en) 2020-04-16 2022-04-12 James F. Kane Compositions comprising milk fat globules and methods of making same
KR102515986B1 (ko) * 2020-07-29 2023-03-29 경희대학교 산학협력단 멜라닌 유사체 나노파티클을 포함하는 단백질 응집 저해용 약학 조성물
CN116832066B (zh) * 2023-08-08 2024-01-12 青岛海洋生物医药研究院股份有限公司 乌贼墨提取物在制备抗多动症和抗抑郁症药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53124636A (en) * 1977-04-04 1978-10-31 Kisaku Mori Method of increasing meranine contained in animal and plant
EP0434750B1 (de) * 1988-09-13 1997-07-09 Biosource Technologies, Inc. Zusammensetzung zur Behandlung von degenerativen Krankheiten des Nervensystems
CA2000114C (en) * 1988-10-03 1995-06-20 Laurence K. Grill Melanin production
ATE204902T1 (de) * 1990-06-29 2001-09-15 Large Scale Biology Corp Melaninproduktion durch transformierte mikroorganismen

Also Published As

Publication number Publication date
US5210076A (en) 1993-05-11
US5817631A (en) 1998-10-06
DE69130859T2 (de) 2000-01-27
JP2002037743A (ja) 2002-02-06
US5776968A (en) 1998-07-07
JP2002058498A (ja) 2002-02-26
WO1992007580A1 (en) 1992-05-14
CA2073180A1 (en) 1992-05-06
EP0510186A1 (de) 1992-10-28
CA2073180C (en) 1998-12-08
ES2131525T3 (es) 1999-08-01
DE69130859D1 (de) 1999-03-18
EP0510186B1 (de) 1999-02-03
JPH05503308A (ja) 1993-06-03
AU9028891A (en) 1992-05-26
EP0510186A4 (en) 1993-03-24
US5703051A (en) 1997-12-30

Similar Documents

Publication Publication Date Title
DE69130859D1 (de) Therapeutische verwendungen von melanin
KR100190454B1 (ko) 모다피닐의 용도
BR9714677A (pt) "enantiÈmeros 3-piridila e seu uso como analgésicos"
ATE219363T1 (de) Lösliche prodrugs von paclitaxel
BG106058A (en) Modulation of excitable tissue function by peripherally administered erythropoietin
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
ATE361093T1 (de) Selektiv auf die leber wirkende pharmazeutisch aktive substanz
FI935847A0 (fi) L-DOPA-esterkompositioner
ATE241365T1 (de) Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen
NL970006I1 (nl) Gebruik van indolon-derivaten voor het bereiden van geneesmiddelen ter behandeling van de ziekte vanParkinson.
DE69840909D1 (de) Analoge von kokain
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ATE198550T1 (de) Verwendung von weihrauch zur behandlung der alzheimer-krankheit
TR199700711T1 (xx) Ciltten ge�erek v�cuda giren form�lasyon.
ATE155038T1 (de) Zusammensetzung zur behandlung von degenerativen krankheiten des nervensystems
YU6196A (sh) Transdermalna flasterska formulacija
WO2002100836A8 (en) Compounds, compositions and methods for modulating beta-amyloid production
PT986393E (pt) Utilizacao de um nitroxido ou de um seu pro-farmaco no tratamento profilactico e terapeutico do cancro
ATE167060T1 (de) Epidermis-wachstumsfaktor als arzneimittel zur wiederherstellung der neuronen der substantia nigra in der behandlung nervenzerstörender störungen
ATE285773T1 (de) Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
ATE359774T1 (de) Taurinderivate verwendbar in der behandlung von netzhauterkrankungen
MX9300205A (es) Compuestos policiclicos disubstituidos y composicion farmaceutica que los contiene.
Verghese et al. A blind controlled trial of adrenocorticotropin and cerebral gangliosides in nerve regeneration in the rat
DE60306503D1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
DE69307702D1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties